 CAMBRIDGE, Mass., July 7, 2021 PRNewswire -- Blueprint Medicines Corporation NASDAQ: BPMC, a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on July 1, 2021, the Compensation Committee of Blueprint Medicines Board of Directors granted non-qualified stock options to purchase an aggregate of 25,762 shares of its common stock and an aggregate of 12,880 restricted stock units RSUs to 12 new employees under Blueprint Medicines 2020 Inducement Plan. 